Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-04-18 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
董事会审计委员会对会计师事务所2024年度履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee of Haichuang Pharmaceutical Co., Ltd. regarding the supervision of the accounting firm Deloitte Huayong for the year 2024. It details the qualifications, audit process, communication, and evaluation of the accounting firm in relation to the company's annual audit work. The document focuses on the audit committee's oversight and assessment of the auditor's performance rather than presenting the full audit report or financial statements. It is a standalone audit-related report describing the audit firm's supervision and quality management, which fits the definition of an Audit Report / Information (AR). The document length is 2571 characters, which is relatively short but contains substantive content about audit supervision, not merely an announcement or certification. Therefore, it should be classified as AR rather than RPA or RNS. FY 2024
2025-04-18 Chinese
2024年度独立董事述职报告-彭永臣
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for a company, detailing the independent director's duties, attendance at meetings, communication with auditors, oversight of financial reporting, internal controls, and governance activities during the 2024 fiscal year. It is a detailed narrative report on the independent director's annual work and evaluation, not a financial statement or audit report itself. It does not contain financial statements or audit opinions but focuses on governance and director responsibilities. This type of document fits best under Board/Management Information (MANG), as it relates to the activities and reporting of a board member rather than a full annual report, audit report, or other financial filings.
2025-04-18 Chinese
2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024 Annual Special Report on the Deposit and Actual Use of Raised Funds" by the company 海创药业股份有限公司. It details the management, usage, and changes related to the company's fundraising activities, including specific amounts raised, usage progress, adjustments to investment projects, and compliance with regulatory requirements. The content focuses on the use of funds raised from an initial public offering (IPO) and the management of those funds, including cash management and project adjustments. This type of report is a specialized disclosure related to capital raising and the use of proceeds, which fits the category of Capital/Financing Update (CAP). It is not a full annual report, audit report, or earnings release, but a detailed update on fundraising and capital usage as required by regulatory guidelines. The document length and detail confirm it is the report itself, not just an announcement of a report publication.
2025-04-18 Chinese
关于续聘公司2025年度财务及内部控制审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's financial and internal control audit firm for the year 2025. It details the auditing firm information, the audit committee's review, independent directors' opinions, and board and supervisory committee approvals. It does not contain actual financial statements or audit reports but rather the company's decision and procedural information about the audit firm appointment. The document length is 3333 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit firm appointment and audit-related information, but it is not a full annual report or audit report itself. However, given the document is an announcement about the audit firm appointment and not the audit report itself, it aligns more closely with Audit Report / Information (AR) rather than Annual Report (10-K) or Report Publication Announcement (RPA). FY 2025
2025-04-18 Chinese
关于提请股东大会授权董事会以简易程序向特定对象发行股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of a company regarding a proposal to seek shareholder authorization for a simplified procedure to issue shares to specific investors. It details the terms, conditions, and procedures for the proposed share issuance, including authorization scope, pricing, use of proceeds, and regulatory compliance. The document is not a full financial report, earnings release, or detailed investor presentation. It is a formal announcement related to capital raising activities and share issuance, specifically requesting shareholder approval for a capital/financing action. The document length is 3425 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-04-18 Chinese
关于为公司及董事、监事、高级管理人员购买责任保险的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company Hai Chuang Pharmaceutical Co., Ltd. regarding the purchase of liability insurance for the company and its directors, supervisors, and senior management. It details the board meeting decisions, insurance coverage, and the independent directors' opinions. The document is an announcement of a corporate governance action related to risk management and insurance, not a financial report, earnings release, or regulatory filing. It is not a report itself but an announcement of a corporate governance matter. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-04-18 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.